0001209191-18-056044.txt : 20181024
0001209191-18-056044.hdr.sgml : 20181024
20181024161549
ACCESSION NUMBER: 0001209191-18-056044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181022
FILED AS OF DATE: 20181024
DATE AS OF CHANGE: 20181024
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arnold Susan Elizabeth
CENTRAL INDEX KEY: 0001755746
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 181136541
MAIL ADDRESS:
STREET 1: C/O PHASEBIO PHARMACEUTICALS, INC.
STREET 2: 1 GREAT VALLEY DRIVE, SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-22
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001755746
Arnold Susan Elizabeth
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
0
1
0
0
VP, Preclinical and Chem.
Common Stock
2018-10-22
4
C
0
2306
A
2306
D
Warrants to Purchase Series B Preferred Stock
0.12
2018-10-22
4
M
0
103
0.00
D
Series B Preferred Stock
103
0
D
Series B Preferred Stock
2018-10-22
4
M
0
103
0.12
A
Common Stock
103
2306
D
Series B Preferred Stock
2018-10-22
4
C
0
2306
0.00
D
Common Stock
2306
0
D
Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
Represents the exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.
/s/ Darren K. DeStefano, Attorney-in-Fact
2018-10-24